All Blogs
Nov 23, 2022
How is Technology Addressing the Sleeping Disorders?
Sleep disorders (or sleep-wake disorders) are one of the major health burdens in today's time. Sleep is a fundamental process in human life and well-being, and these disorders largely remain untreated or, more often, misdiagnosed as psychiatric problems. Sleep disorders affect and change the way that a person sleep...
Read More...
Nov 22, 2022
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL
Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...
Read More...
Nov 21, 2022
RNA Interference: New Class of Drugs In The Fight Against Disease
RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...
Read More...
Nov 17, 2022
Medtronic Launches Infusion Set for Insulin Pumps; Penumbra’s Virtual Reality-Based Rehabilitation System; FDA Approval to Genesis’s Chocolate Touch® Drug-coated Balloon PTA Catheter; FDA Nod to AEYE’s AI-based Autonomous Screening; Alpheus Medical Treats First High-Grade Glioma Brain Cancer Patient with its Proprietary Platform; Karidum’s Next Generation Globe® Pulsed Field System
Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US On November 15, 2022, Medtronic plc, a global leader in healthcare technology, announced the US launch of the Medtronic Extended infusion set, the first and only infusion set labeled for up to ...
Read More...
Nov 18, 2022
Gene Therapy: The Next Milestone in Treating Complex Diseases
Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy w...
Read More...
Nov 16, 2022
Insights Into the Key Advancements Transforming the Type 2 Diabetes Treatment and Management
Diabetes is a chronic metabolic disorder that is influenced by a wide variety of factors and is characterized by high or low blood glucose (or blood sugar) levels in the body. Diabetes is a major risk factor for blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Also, it can significantly ...
Read More...
Nov 15, 2022
Genentech’s gantenerumab Fails in Phase III Trial; CHMP Recommends’ Dupixent; FDA Clears Imfinzi and Imjudo with chemotherapy; NICE Recommends Ipsen’s Cabometyx (cabozantinib); NICE Backs KEYTRUDA; NRG Announces £16 Million Series A Funding; FDA Backs AstraZeneca’s PT027
Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...
Read More...
Nov 14, 2022
Novel Insights Into The Non-Small Cell Lung Cancer Market
Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. As per the American Cancer Society, almost 230K new cases were diagnosed in 2022 alone, and almost 130K deaths from lung cancer were recorded in the same year. Studies show that non-small cel...
Read More...
Nov 11, 2022
How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle its Treatment Landscape
Cutaneous T-cell lymphoma (CTCLs) characterized by cutaneous infiltration of malignant monoclonal T-lymphocytes is a rare lymphoma affecting around 6.4 cases per million individuals every year. The total incident population of Cutaneous T-cell lymphoma in the 7MM was around 7.5K in 2021, with the US accounting for ...
Read More...
Nov 10, 2022
QuantuMDx & Menarini’s Agreement; TruClear System Launched by Medtronic in India; FDA 510(k) Clearance for TriVerse Primary Knee Replacement System; FDA Clearance to ProciseDx’s Reactive Protein (CRP) Assay and ProciseDx Instrument; Evolution Optiks’s Enrollment of LFR-260 Phoropter in US; Kardium First-in-Human Clinical Study of the New Globe Pulsed Field System
QuantuMDx and Menarini Announced an Agreement for the Distribution of the Q-POCTM Platform On November 2, 2022, QuantuMDx Group Limited, a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), announced an exclusive distribution agreement for Qu...
Read More...